Hsbc Holdings PLC Increases Stock Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Hsbc Holdings PLC increased its holdings in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 180.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,694 shares of the company’s stock after purchasing an additional 2,377 shares during the period. Hsbc Holdings PLC’s holdings in BeOne Medicines were worth $1,124,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. EFG International AG purchased a new stake in BeOne Medicines during the fourth quarter worth $25,000. Leonteq Securities AG purchased a new position in shares of BeOne Medicines in the 4th quarter valued at $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines in the 2nd quarter worth $35,000. CWM LLC raised its position in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the 4th quarter worth $61,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 6th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Barclays lifted their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $391.38.

BeOne Medicines Stock Up 1.8%

Shares of ONC stock opened at $303.96 on Tuesday. The stock’s fifty day moving average price is $290.06 and its 200 day moving average price is $308.94. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $249.12 and a 1-year high of $385.22. The company has a market cap of $33.35 billion, a price-to-earnings ratio of 68.00 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Xiaobin Wu sold 1,292 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $276.26, for a total value of $356,927.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Titus B. Ball sold 169 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $257.20, for a total transaction of $43,466.80. Following the transaction, the insider directly owned 99,645 shares of the company’s stock, valued at $25,628,694. This represents a 0.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 27,568 shares of company stock valued at $7,452,336. 6.19% of the stock is owned by corporate insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.